Chinese Herb Reverses Memory Loss in Alzheimer’s Mice by Fixing Gut Bacteria

If you've gone down the internet rabbit hole linking gut health to brain health, you've probably hit a stubborn question: is that connection real, or wishful thinking? A new mouse study out of Fujian Medical University adds some of the most direct evidence yet that it can be real, at least in an animal model of Alzheimer's disease. Researchers gave mice a compound extracted from astragalus root, a staple of traditional Chinese medicine, and watched it reshape gut bacteria, calm brain inflammation, and reverse memory loss. Then, to rule out coincidence, they transplanted those reshaped gut bacteria alone into a separate batch of sick mice and got the same result.

Key takeaways

• Astragalus polysaccharide (APS), a compound from a traditional Chinese herb, reversed memory deficits and reduced amyloid plaques in 5xFAD mice, a genetically engineered mouse model of Alzheimer's disease.
• Transplanting gut bacteria alone from APS-treated mice into untreated sick mice reproduced the memory improvement, showing the microbes themselves were doing causal work, not just the herb.
• This is preclinical, mouse-only research using a single accelerated genetic model in males only; there is no human evidence, and the right dose and broader applicability remain unknown.

Astragalus Polysaccharide Reversed Memory Loss in 5xFAD Mice

Researchers gave male 5xFAD mice, a genetically engineered strain that carries five human Alzheimer's mutations and rapidly develops brain amyloid buildup, oral doses of astragalus polysaccharide (APS) at 200 mg per kilogram of body weight daily for 60 days, according to the study, published in Frontiers in Pharmacology. Untreated 5xFAD mice took significantly longer to find a hidden platform in the Morris water maze, a standard test of spatial memory, than healthy mice. APS-treated mice closed much of that gap: they reached the platform faster, crossed its former location more often, and spent more time searching the correct area of the pool, all without any change in how fast or how far they swam, which rules out a simple energy or motor effect. Blood work and liver and kidney markers showed no signs of toxicity from the treatment.

Why Gut-Brain Findings Matter for Dementia Research

Gut microbiota dysbiosis, an imbalance in the trillions of bacteria living in the intestines, is a well documented feature of Alzheimer's disease, and a growing body of research links disrupted gut bacteria to worsened brain inflammation through pathways that affect the gut lining, the blood brain barrier, and circulating immune signals. That matters beyond Alzheimer's: the same gut-immune-brain wiring has been implicated in depression, autoimmune disease, and inflammatory bowel conditions, which is part of why researchers increasingly treat the gut as a target with effects across multiple disease pathways rather than a bystander. In the 5xFAD mice, the researchers found that diseased animals had reduced gut bacterial diversity compared to healthy mice, consistent with that broader pattern, and that APS partially restored it, shifting the gut community back toward a healthy-mouse profile.

Fecal Transplants Confirmed Gut Bacteria Drove the Effect

To test whether the gut bacteria were actually causing the improvement, rather than just changing alongside it, the team ran a second experiment using fecal microbiota transplantation (FMT), a technique that transfers gut bacteria from one animal to another. They split sick mice into three groups: one received bacteria from untreated 5xFAD donors, one received bacteria from saline-treated 5xFAD donors, and one received bacteria from APS-treated 5xFAD donors, delivered weekly for eight weeks after an initial antibiotic pretreatment. Mice that received bacteria from APS-treated donors performed better on the water maze than either control group, despite never receiving APS themselves. They also showed less microglial activation (microglia are the brain's resident immune cells, and their overactivation drives neuroinflammation), lower levels of the inflammatory signals IL-6 and TNF-alpha, and higher levels of the anti-inflammatory marker TGF-beta1. This lines up with other fecal transplant experiments in Alzheimer's mouse models that have reduced brain pathology and improved cognition, reinforcing that gut bacteria alone can move the needle on brain outcomes in these animals.

What This Means, and Doesn't Mean, for People Worried About Memory Loss

This is not a signal to start taking astragalus supplements for memory protection. What it does show is a fairly complete mechanistic chain in mice: an herbal compound changed gut bacteria, specific bacterial shifts (including enrichment of Lactobacillus reuteri and a Lachnospiraceae species tied to gut barrier support and short-chain fatty acid production) tracked with less brain inflammation, and transplanting just the bacteria reproduced the cognitive benefit. In treated mice, amyloid-beta plaque buildup, the sticky protein clumps that are a hallmark of Alzheimer's pathology, dropped sharply, and levels of PSD-95 and syntaxin, two proteins that mark healthy connections between brain cells, partially recovered. For a reader tracking their own or a family member's memory concerns, the honest takeaway is that this adds weight to the idea that the gut plays an active role in dementia-related brain changes, not that a specific supplement or fix is ready to use.

Why These Results Don't Prove Astragalus Works in People

Several limits keep this from translating directly to humans. The 5xFAD model carries an aggressive combination of five inherited mutations that cause early, fast amyloid buildup, which does not resemble the slower, more common form of Alzheimer's most people develop. The researchers used only male mice, explicitly to avoid the confounding effects of estrogen on gut bacteria and treatment response, so it is unknown whether female mice, let alone women, would respond the same way. No human trials of this dosing or approach exist yet, and the effective human dose, if any, has not been established.

What Comes Next for Astragalus and Gut-Targeted Alzheimer's Therapies

One detail the researchers flagged as worth chasing: in APS-treated mice, TREM2 (a microglial receptor tied to plaque cleanup), TGF-beta1, and PSD-95 all rose not just back to healthy-mouse levels but above them, an overshoot the authors describe as possibly reflecting a rebound repair response, though they say the mechanism isn't yet clear. That, along with the need to confirm the effect in other Alzheimer's models, in female animals, and eventually in people, is the next phase of work the authors call for before astragalus-derived or other gut-targeted compounds could be considered candidates for human dementia care.

Common Questions

What is astragalus polysaccharide? It's a carbohydrate compound extracted from the root of Astragalus membranaceus, an herb long used in traditional Chinese medicine, and studied here for its effects on gut bacteria and inflammation.

Does this mean astragalus supplements can treat Alzheimer's in people? No. This study was done entirely in mice with an aggressive genetic model of the disease; there is no human data on astragalus for Alzheimer's prevention or treatment.

How did researchers prove the gut bacteria, not just the herb, caused the improvement? They transplanted gut bacteria from APS-treated mice into separate, untreated sick mice and saw the same memory and inflammation improvements, even though those mice never received the herb directly.

What specific gut bacteria changed with treatment? APS-treated mice showed enrichment of Lactobacillus reuteri and an unidentified Lachnospiraceae genus, both linked in prior research to gut barrier support and production of protective short-chain fatty acids.

References

1. Xiaoli Cui, Zhen Wei, Qingshui Wang, et al. (2026). Astragalus polysaccharide alleviates neuropathology and cognitive deficits by modulating gut microbiota and neuroinflammation in an Alzheimer’s disease model. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2026.1830927
2. Gut Microbiota and Dysbiosis in Alzheimer's Disease: Implications for Pathogenesis and Treatment. NIH. https://pmc.ncbi.nlm.nih.gov/articles/PMC7541367/
3. Linkai Qu, Yanwei Li, Fan Liu, et al. (2023). Microbiota-Gut-Brain Axis Dysregulation in Alzheimer's Disease: Multi-Pathway Effects and Therapeutic Potential. Aging and disease. https://doi.org/10.14336/ad.2023.0823-2
4. Shalini Elangovan, Thomas J. Borody, R. M. Damian Holsinger (2022). Fecal Microbiota Transplantation Reduces Pathology and Improves Cognition in a Mouse Model of Alzheimer’s Disease. Cells. https://doi.org/10.3390/cells12010119